Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 21.00% and closed at $1.21, with the total traded volume of 47,354.00 shares. During last trade its minimum price was $1.00 and it gained its highest price of $1.24 and has a total of 40.91 million outstanding shares.
On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.
Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)
Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.
“I love my work, especially when it allows me to bring my passion for health and business development together, and to bring them to other people,’ says Foster-Cunningham. “This project is my new baby, and I’m excited about the prospects of helping it grow to maturity.”
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) showing dropped of -19.27% and closed at $0.880, after gaining total volume of 8.33M shares. Its earnings per share (EPS) is -$0.01 and its beta value stands at -6.02 points and has total market capitalization of $211.72 million and a total of 135.31 million outstanding shares.
OWC Pharmaceutical Research Corp (OWCP) on April 5, 2017 announced it has received expressions of interest from the scientific and medical communities world-wide as a result of its recently announce positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis.
OWCP’s scientific team, led by the renowned Dr. Yehuda Baruch, the Company’s Chief Science Officer and OWC’s Director of Research and Regulatory Affairs, and former Director of Israel’s Ministry of Health Medical Management Division, previously reported trial results and concluded that post-application of OWC’s unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis. These promising results have led the Company to expand the size and scope of its clinical study and has led directly to OWC’s receipt of continuing inquiries and expressions of interest from researchers world-wide for more information on the cannabinoid-based topical cream for treatment of psoriasis and our product’s anticipated availability for use in the market.
Mr. Ziv Turner, OWC’s, Managing Director, commented, “As soon as we announced the efficacy results of our pre-clinical psoriasis treatment, OWC has continued to receive active inquiries from a variety of leading international scientific institutions in Countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We are currently in negotiations for scientific and marketing cooperation agreements. In addition, we realistically expect product readiness for our topical cream in early Q3 2017 and, subject to regulatory approvals, federal and states laws we will be able to offer our topical cream to those who suffer from psoriasis.”
Kush Bottles Inc (OTCMKTS:KSHB) decreased -3.55% closed at $2.72 and traded with total volume of 117,259.00 shares, while the average trading remained 147,587.00 shares. During last trade its minimum price was $2.68 and it gained the highest price of $2.88. Its market capitalization was $135.28 million.
Kush Bottles Inc (KSHB) on March 23, 2017 announced that on July 1, 2017, it will move its corporate headquarters and California fulfillment center to a larger, more centrally located facility in Garden Grove, CA. The new building features greater warehouse space to allow for increased inventory, as well as additional floor space to support new services for the company’s growing customer base.
A recent report from the World Bank stated that California just surpassed the nation of France to become the world’s sixth largest economy, only outpaced by the US (as a whole), China, Japan, Germany, and the UK.
According to an article in Business Insider, the size of the cannabis market in California could reach $4.27 billion in 2018, and could grow to $6.45 billion by 2020.
Bolstering this projected growth are two recent voter-approved initiatives: Proposition 64, the “Adult Use of Marijuana Act” legalized the purchase of cannabis for adults 21 and older in California; and Measure M, which was recently passed in Los Angeles and will allow the nation’s second largest city to repeal a current ban on medical marijuana dispensaries. The measure also allows the city council to create new rules in order to facilitate a safe and well-regulated legal cannabis industry.
“Kush Bottles thrives in regulated cannabis markets, where strict rules require the use of certified, child resistant packaging,” said Nick Kovacevich, CEO of Kush Bottles, Inc. “We are excited about the passage of Measure M, which will allow newly established and existing medical marijuana facilities to legally operate in Los Angeles under new rules to create a safe and well-regulated market.”